Abstract:figure legend Hypertension is a common adverse effect of calcineurin inhibitors, but the underlying mechanism is enigmatic. Under normal conditions, calcineurin constitutively dephosphorylates both NMDARs and AMPARs, limiting their interactions with α2δ‐1 proteins in the hypothalamic paraventricular nucleus (PVN). This leads to minimal presynaptic and postsynaptic expression of NMDARs. Additionally, α2δ‐1‐free GluA1 and GluA2 subunits predominantly assemble into GluA1/GluA2 heterotetramers (Ca2+‐impermeable) for postsynaptic incorporation. When calcineurin is inhibited, the phosphorylation of NMDARs and AMPARs is increased, facilitating their direct interactions with α2δ‐1. Consequently, α2δ‐1 promotes NMDAR trafficking to both presynaptic and postsynaptic sites. Furthermore, binding with α2δ‐1 disrupts GluA1/GluA2 heteromeric assembly, but not GluA1 homomeric assembly, resulting in the switch of postsynaptic AMPARs to GluA1 homotetramers (Ca2+‐permeable). Together, increased synaptic expression of NMDARs and Ca2+‐permeable AMPARs augments glutamatergic input to the PVN, which drives sympathetic outflow in calcineurin inhibitor‐induced hypertension. Hypertension is a major adverse effect of calcineurin inhibitors, such as tacrolimus (FK506) and cyclosporine, used clinically as immunosuppressants. Calcineurin inhibitor‐induced hypertension (CIH) is linked to augmented sympathetic output from the hypothalamic paraventricular nucleus (PVN). GluA2‐lacking, Ca2+‐permeable AMPA receptors (CP‐AMPARs) are a key feature of glutamatergic synaptic plasticity, yet their role in CIH remains elusive. Here, we found that systemic administration of FK506 in rats significantly increased serine phosphorylation of GluA1 and GluA2 in PVN synaptosomes. Strikingly, FK506 treatment reduced GluA1/GluA2 heteromers in both synaptosomes and endoplasmic reticulum‐enriched fractions from the PVN. Blocking CP‐AMPARs with IEM‐1460 induced a larger reduction of AMPAR‐mediated excitatory postsynaptic current (AMPAR‐EPSC) amplitudes in retrogradely labelled, spinally projecting PVN neurons in FK506‐treated rats than in vehicle‐treated rats. Furthermore, FK506 treatment shifted the current–voltage relationship of AMPAR‐EPSCs from linear to inward rectification in labelled PVN neurons. FK506 treatment profoundly enhanced physical interactions of α2δ‐1 with GluA1 and GluA2 in the PVN. Inhibiting α2δ‐1 with gabapentin, α2δ‐1 genetic knockout, or disrupting α2δ‐1–AMPAR interactions with an α2δ‐1 C terminus peptide restored GluA1/GluA2 heteromers in the PVN and diminished inward rectification of AMPAR‐EPSCs in labelled PVN neurons induced by FK506 treatment. Additionally, microinjection of IEM‐1460 or α2δ‐1 C terminus peptide into the PVN reduced renal sympathetic nerve discharges and arterial blood pressure elevated in FK506‐treated rats but not in vehicle‐treated rats. Thus, calcineurin in the hypothalamus constitutively regulates AMPAR subunit composition and phenotypes by controlling GluA1/GluA2 interactions with α2δ‐1. Synaptic CP‐AMPARs in PVN presympathetic neurons contribute to augmented sympathetic outflow in CIH. Key points Systemic treatment with the calcineurin inhibitor increases serine phosphorylation of synaptic GluA1 and GluA2 in the PVN. Calcineurin inhibition enhances the prevalence of postsynaptic Ca2+‐permeable AMPARs in PVN presympathetic neurons. Calcineurin inhibition potentiates α2δ‐1 interactions with GluA1 and GluA2, disrupting intracellular assembly of GluA1/GluA2 heterotetramers in the PVN. Blocking Ca2+‐permeable AMPARs or α2δ‐1–AMPAR interactions in the PVN attenuates sympathetic outflow augmented by the calcineurin inhibitor.

Calcineurin inhibition, cardiovascular consequences, vascular resistance, and potential responses

Calcineurin Is a Universal Regulator of Vessel Function—Focus on Vascular Smooth Muscle Cells

Calcineurin Inhibitor Attenuates the Development and Induces the Regression of Cardiac Hypertrophy in Rats with Salt-Sensitive Hypertension.

Calcineurin inhibitors and the renin–angiotensin–aldosterone system

Calcineurin Plays a Critical Role in Pressure Overload–Induced Cardiac Hypertrophy

Role of calcineurin in regulating renal potassium (K+) excretion: Mechanisms of calcineurin inhibitor‐induced hyperkalemia

Calcineurin-dependent ion channel regulation in heart.

Carabin: Endogenous Calcineurin Inhibitor, a Potential Diagnostic and Therapeutic Target for Cardiac Hypertrophy in Heart Failure

Management of Calcineurin Inhibitors-Related Chronic Kidney Disease in Cardiac Transplantation

Cellular And Molecular Consequences Of Calcineurin A Alpha Gene Deletion

The effect of calcineurin inhibitors on endothelial function in renal transplant recipients

Effects of combination of irbesartan and perindopril on calcineurin expression and sarcoplasmic reticulum Ca 2+ -ATPase activity in rat cardiac pressure-overload hypertrophy

Calcineurin regulates synaptic Ca2+‐permeable AMPA receptors in hypothalamic presympathetic neurons via α2δ‐1‐mediated GluA1/GluA2 assembly

Calcineurin (PPP3CB) regulates angiotensin II-dependent vascular remodelling by potentiating EGFR signalling in mice

Calcineurin and electrical remodeling in pathologic cardiac hypertrophy.

Calcineurin B Subunit Acts As a Potential Agent for Preventing Cardiac Ischemia/reperfusion Injury

Ablation of calcineurin Aβ reveals hyperlipidemia and signaling cross-talks with phosphodiesterases.

Involvement of Calcineurin in Angiotensin II-induced Cardiomyocyte Hypertrophy and Cardiac Fibroblast Hyperplasia of Rats

Regulators of Calcineurin 1 Deficiency Attenuates Tubulointerstitial Fibrosis Through Improving Mitochondrial Fitness.

A13710 Calcineurin Dephosphorylates and Regulates the Ubiquitin Ligase Kelch-like 3

Abstract 068: Kelch-Like 3 Dephosphorylation by Calcineurin As a Mechanism Regulating Na-cl Cotransporter